3.0 Selection of Patients 
Patients will be carefully selected based on consideration 
of their past medical history and present status. The referring 
physician, the attending physician, and surgical oncology or the 
relevant clinical department, the patient, and family members 
will make a joint decision regarding the appropriate treatment 
with conventional therapy. If surgery, chemotherapy, or 
radiation are deemed unlikely to provide further benefit to the 
patient, the opportunity to pursue this experimental protocol 
will be offered to the patient. The following criteria will be 
used to select appropriate patients for study: 
3.1 Criteria for Patient Eligibility 
3.1.1 Patients must be HLA-B7 negative. 
3.1.2 Patients with cutaneous tumor nodules will be 
preferred in patients undergoing intratumor 
injection. 
3.1.3 The patient's disease will be unresponsive to 
standard modes of treatment. 
3.1.4 Patient must be greater than 18 years of age. 
3.1.5 The patient must not have antibodies to the 
human immunodeficiency virus. 
3.1.6 The patient must be able to provide informed 
consent. 
3.1.7 Estimated life expectancy >2 months. 
3.2 Criteria for Patient Ineligibility 
3.2.1 Patients with active autoimmune disease or 
infection. 
[708] 
Recombinant DNA Research, Volume 17 
